

Chapter 15

REFERENCES

1. Wiklund RA. Preoperative preparation of patients with advanced liver disease. *Crit Care Med*. 2004;32:S106.
2. Rappaport AM. The microcirculatory acinar concept of normal and pathological hepatic structure. *Beitr Pathol*. 1976;157:215.
3. Ishak KG, Zimmerman HJ, Ray MB. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. *Alcohol Clin Exp Res*. 1991;15:45.
4. Baker AL. Hepatotrophic factors: basic concepts and clinical implications. *Acta Med Scand Suppl*. 1985;703:201.
5. Yoshida T, Ninomiya K, Matsumoto T, Baatar D, Bandoh T, Kitano S. Glucagon and insulin metabolism in cirrhotic patients. *Hepatogastroenterology*. 1998;45:468.
6. Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. *Exp Clin Endocrinol Diabetes*. 1995;103:63.
7. Pantuck EJ. Plasma cholinesterase: gene and variations. *Anesth Analg*. 1993;77(2):380.
8. Rivard GE, Kovac I, Kunschak M, Thone P. Clinical study of recovery and half-life of vapor-heated factor VII concentrate. *Transfusion*. 1994;34:975.
9. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg*. 1973;60:646.
10. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. *CMAJ*. 2005;172:367.
11. Whalen E. Liver imaging—current trends in MRI, CT, and US: international symposium and course, June 1990. *AJR Am J Roentgenol*. 1990;155:1125.
12. Tandon BN, Rana S, Acharya SK. Bedside ultrasonography. A low-cost definitive diagnostic procedure in obstructive jaundice. *J Clin Gastroenterol*. 1987;9:353.
13. Zeman RK, Fox SH, Silverman PM, et al. Helical (spiral) CT of the abdomen. *AJR Am J Roentgenol*. 1993;160:719.
14. Silverman PM, Roberts S, Tefft MC, et al. Helical CT of the liver: clinical application of an automated computer technique, SmartPrep, for obtaining images with optimal contrast enhancement. *AJR Am J Roentgenol*. 1995;165:73.
15. Regan LS. Screening for hepatocellular carcinoma in high-risk individuals. A clinical review. *Arch Intern Med*. 1989;149:1741.
16. Gelman SI. Disturbances in hepatic blood flow during anesthesia and surgery. *Arch Surg*. 1976;111:881.
17. Branch RA. Is there increased cerebral sensitivity to benzodiazepines in chronic liver disease? *Hepatology*. 1987;7:773.
18. Ferenci P, Grimm G, Meryn S, Gangl A. Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. *Gastroenterology*. 1989;96:240.
19. Ostergaard D, Viby-Mogensen J, Rasmussen SN, Gatke MR, Varin F. Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. *Anesthesiology*. 2005;102:1124.
20. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. *The Liver and Portal Hypertension*. Philadelphia, PA: WB Saunders; 1964:1.
21. Garrison RN, Cryer HM, Howard DA, Polk HC Jr. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. *Ann Surg*. 1984;199:648.
22. Mansour A, Watson W, Shayani V, Pickleman J. Abdominal operations in patients with cirrhosis: still a major surgical challenge. *Surgery*. 1997;122:730.
23. Aranha GV, Sontag SJ, Greenlee HB. Cholecystectomy in cirrhotic patients: a formidable operation. *Am J Surg*. 1982;143:55.
24. Aranha GV, Kruss D, Greenlee HB. Therapeutic options for biliary tract disease in advanced cirrhosis. *Am J Surg*. 1988;155:374.
25. Fernandes NF, Schwesinger WH, Hilsenbeck SG, et al. Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. *Liver Transpl*. 2000;6:340.
26. Malinchoc M, Kamath PS, Gordon, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology*. 2000;31:864-871.
27. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology*. 2003;124:91-96.
28. Northup PG, Wanamaker RC, Lee VD, et al. The Model for End-Stage Liver Disease (MELD) score as a predictor of non-transplant surgical mortality in patients with cirrhosis. *Ann Surg*. 2005;242:244-251.
29. Friedman LS. Surgery in the patient with liver disease. *Trans Am Clin Climatol Assoc*. 2010;121:192-204.
30. Befeler AS, Palmer DE, Hoffman, et al. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. *Arch Surg*. 2005;140(7):650-654.
31. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). *Hepatology*. 2007;45(3):797-805.

32. Teh SH, Christein J, Donohue J, et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: MELD score predicts perioperative mortality. *J Gastrointest Surg.* 2005;9:1207-1215.
33. Cucchetti A, Ercolani G, Vivarelli M, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. *Liver Transpl.* 2006;12(6):966-971.
34. Befeler AS, Palmer DE, Hoffman M, et al. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. *Arch Surg.* 2005;140:650-654.
35. Perkins L, Jeffries M, Patel T. Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis. *Clin Gastroenterol Hepatol.* 2004;2(12):1123-1128.
36. Suman A, Barnes DS, Zein NN, et al. Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. *Clin Gastroenterol Hepatol.* 2004;80:719-723.
37. Yu AS, Ahmed A, Keeffe EB. Liver transplantation: evolving patient selection criteria. *Can J Gastroenterol.* 2001;15:729.
38. Brown RS Jr, Kumar KS, Russo MW, et al. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. *Liver Transpl.* 2002;8:278.
39. Gomori JM, Horev G, Tamary H, et al. Hepatic iron overload: quantitative MR imaging. *Radiology.* 1991;179:367.
40. Wolfsdorf JL, Weinstein DA. Glycogen storage diseases. *Rev Endocr Metab Disord.* 2003;4:95.
41. Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med.* 2002;346:1221.
42. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. *Am J Gastroenterol.* 1999;94:3010.
43. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol.* 2003;98:960.
44. Clain DJ, Lefkowitz JH. Fatty liver disease in morbid obesity. *Gastroenterol Clin North Am.* 1987;16:239.
45. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. *Semin Liver Dis.* 2001;21:27.
46. Charlton M, Kasparova P, Weston S, et al. Frequency of non-alcoholic steatohepatitis as a cause of advanced liver disease. *Liver Transpl.* 2001;7:608.
47. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. *N Engl J Med.* 1997;336:347.
48. Kumar A, Beniwal M, Kar P, Sharma JB, Murthy NS. Hepatitis E in pregnancy. *Int J Gynaecol Obstet.* 2004;85:240.
49. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. The Incident Investigation Teams and others. *N Engl J Med.* 1997;336:178.
50. Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. *Am J Pathol.* 2000;156:1117.
51. Kleinman S. Hepatitis G virus biology, epidemiology, and clinical manifestations: Implications for blood safety. *Transfus Med Rev.* 2001;15:201.
52. Alter MJ, Gallagher M, Morris TT, et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. *N Engl J Med.* 1997;336:741.
53. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med.* 2002;137(12):947.
54. Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. *Chest.* 2002;121:1638.
55. Kaplan M, Cimen S, Kut MS, Demirtas MM. Cardiac operations for patients with chronic liver disease. *Heart Surg Forum.* 2002;5:60.
56. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by ace tlycysteine of hemodynamics and oxygen transport in fulminant hepatic failure. *N Engl J Med.* 1991;324:1852.
57. Summary of the national Halothane Study. Possible association between halothane anesthesia and postoperative hepatic necrosis. *JAMA.* 1966;197:775.
58. Bunker JP. Final report of the National Halothane Study. *Anesthesiology.* 1968;29:231.
59. Krawitt EL. Autoimmune hepatitis. *N Engl J Med.* 1996;334:897.
60. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. *Hepatology.* 1993;18:998.
61. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. *Hepatology.* 1992;15:215.
62. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. *Hepatology.* 1988;8:781.
63. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. *N Engl J Med.* 2005;353:1261.
64. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. *Hepatology.* 1989;10:1.
65. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. *Hepatology.* 1989;10:430.
66. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. *Semin Liver Dis.* 1991;11:31.
67. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. *N Engl J Med.* 1997;337:898.
68. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. *N Engl J Med.* 2003;349:583.
69. Kumar KS, Lefkowitz J, Russo MW, et al. Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis. *Gastroenterology.* 2002;122:2026.
70. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. *Gastroenterology.* 2004;127:S72.
71. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. *Best Pract Res Clin Gastroenterol.* 2005;19:3.
72. Chen MF, Tsai HP, Jeng LB, et al. Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis. *World J Surg.* 2003;27:443.
73. Choi D, Lim JH, Hong ST. Relation of cholangiocarcinomas to clonorchiasis and bile duct stones. *Abdom Imaging.* 2004;29:590.

74. Dooley JS, Dick R, George P, Kirk RM, Hobbs KE, Sherlock S. Percutaneous transhepatic endoprosthesis for bile duct obstruction. Complications and results. *Gastroenterology*. 1984;86:905.
75. Bogin V, Marcos A, Shaw-Stiffel T. Budd-Chiari syndrome: in evolution. *Eur J Gastroenterol Hepatol*. 2005;17:33.
76. Sharma S, Texeira A, Texeira P, Elias E, Wilde J, Olliff SP. Pharmacological thrombolysis in Budd-Chiari syndrome: a single centre experience and review of the literature. *J Hepatol*. 2004;40:172.
77. Klein AS, Molmenti EP. Surgical treatment of Budd-Chiari syndrome. *Liver Transpl*. 2003;9(9):891.
78. Palmes D, Skawran S, Spiegel HU. Acute liver failure: from bench to bedside. *Transplant Proc*. 2005;37:1628.
79. O'Grady JG. Acute liver failure. *Postgrad Med J*. 2005;81:148.
80. Sherlock S, Dooley J. Fulminant hepatic failure. In: Sherlock S, Dooley J (eds). *Diseases of the Liver and Biliary System*. 9th ed. London, UK: Blackwell Scientific; 1993:102.
81. Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? *N Engl J Med*. 2001;344:452.
82. Bac DJ. Spontaneous bacterial peritonitis: an indication for liver transplantation? *Scand J Gastroenterol Suppl*. 1996;218:38.
83. Venturini I, Corsi L, Avallone R, et al. Ammonia and endogenous benzodiazepine-like compounds in the pathogenesis of hepatic encephalopathy. *Scand J Gastroenterol*. 2001;36:423.
84. Riordan SM, Williams R. Treatment of hepatic encephalopathy. *N Engl J Med*. 1997;337:473.
85. Hayashida N, Shoujima T, Teshima H, et al. Clinical outcome after cardiac operations in patients with cirrhosis. *Ann Thorac Surg*. 2004;77:500.
86. Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tscheliessnigg KH. Combined coronary artery bypass grafting and orthotopic liver transplantation: a case report. *Transplant Proc*. 2003;35:817.
87. Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. *Hepatology*. 1997;25:1282.
88. Cremona G, Higenbottam TW, Mayoral V, et al. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. *Eur Respir J*. 1995;8:1883.
89. Krowka MJ, Cortese DA. Hepatopulmonary syndrome. Current concepts in diagnostic and therapeutic considerations. *Chest*. 1994;105:1528.
90. Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. *Mayo Clin Proc*. 1996;71:543.
91. Collisson EA, Nourmand H, Fraiman MH, et al. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. *Liver Transpl*. 2002;8:925.
92. Guevara M, Ginès P. Hepatorenal syndrome. *Dig Dis*. 2005;23(1):47-55.
93. Moreau R. Hepatorenal syndrome in patients with cirrhosis. *J Gastroenterol Hepatol*. 2002;17:739.
94. Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. *Gastroenterology*. 2003;124(6):1700.
95. Kujovich JL. Hemostatic defects in end-stage liver disease. *Crit Care Clin*. 2005;21:563.
96. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. *Thromb Haemost*. 2005;93:1027.
97. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. *Crit Care Med*. 2005;33:883.
98. Lyew MA, Isaacson IJ. Template for rapid analysis of the thrombelastogram. *Anesth Analg*. 1992;74:782.
99. Clayton DG, Miro AM, Kramer DJ, Rodman N, Wearden S. Quantification of thrombelastographic changes after blood component transfusion in patients with liver disease in the intensive care unit. *Anesth Analg*. 1995;81:272.
100. Lata J, Hulek P, Vanasek T. Management of acute variceal bleeding. *Dig Dis*. 2003;21:6.
101. Brown MW. Gastroesophageal varices. Management of hemorrhage in the cirrhotic patient. *Prim Care*. 1988;15:175.
102. Grace ND. A hepatologist's view of variceal bleeding. *Am J Surg*. 1990;160:26.
103. Gordon JD, Colapinto RF, Abecassis M, et al. Transjugular intrahepatic portosystemic shunt: a nonoperative approach to life-threatening variceal bleeding. *Can J Surg*. 1987;30:45.
104. Shiffman ML, Jeffers L, Hoofnagle JH, Tralka TS. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. *Hepatology*. 1995;22:1591.
105. Garcia-Pagan JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. *N Engl J Med*. 2010; 362:2370.
106. Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP 3rd, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. *Hepatology*. 1994;20:46.
107. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. *N Engl J Med*. 1996;334:246.
108. Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. *Hepatology*. 1989;10:958.
109. Inturri P, Graziotto A, Rossaro L. Treatment of ascites: old and new remedies. *Dig Dis*. 1996;14:145.
110. Rosemurgy AS, Zervos EE, Clark WC, et al. TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. *Ann Surg*. 2004;239:883.
111. Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. *J Hepatol*. 1986;3:75.
112. Morgan MY. The treatment of chronic hepatic encephalopathy. *Hepatogastroenterology*. 1991;38:377.
113. Horslen SP, Hammel JM, Fristoe LW, et al. Extracorporeal liver perfusion using human and pig livers for acute liver failure. *Transplantation*. 2000;70:1472.
114. Sechser A, Osorio J, Freise C, Osorio RW. Artificial liver support devices for fulminant liver failure. *Clin Liver Dis*. 2001;5:415.